European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
The European Commission granted marketing authorization for POHERDY, the first biosimilar to PERJETA, developed in partnership with Shanghai Henlius Biotech. Organon holds exclusive commercialization rights for POHERDY globally, excluding China, securing a foothold in the European market for HER2-positive breast cancer treatments.
Key figures
- Drug Name
- POHERDY (pertuzumab)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.